Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Vesugen
Vesugen (also transliterated Vezugen) is the tripeptide Lys-Glu-Asp, known as KED or T-38 in the papers of Vladimir Khavinson's St.
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context, not a protocol or recommendation.
Mass amounts available for comparison
- Lower range1 mgDose
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range5 mgDose
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Reported protocols for Vesugen
What published studies and recent community write-ups report about amounts, timing and course length. 2 preclinical and 3 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Preclinical2 rows | |||||
| Alzheimer's disease mouse model (5xFAD)5xFAD transgenic mice treated from 2 to 4 months of age | 400 mcg/kg per day | Once daily | Intraperitoneal injection | About 2 monthsNot applicable | Pharmaceuticals (PubMed)2021 |
| Daily KED tended to increase neuroplasticity markers, and KED and the related tripeptide EDR (Pinealon) prevented loss of dendritic spines in the mice. This is the only PubMed-indexed in vivo dose for the peptide, it addresses a brain endpoint rather than a vascular one, and the developers are the authors. | |||||
| Vascular explants and endothelial cell cultures from young and old ratsOrganotypic aortic tissue cultures from 3-month and 24-month Wistar rats, and dissociated rat aortic endothelial cells at passage 3 and passage 14 | 0.05 ng/mL (organotypic explants) and 20 ng/mL (dissociated cultures) | Added once to the culture medium | In vitro | 3 days of cultureNot applicable | Community resource2015 |
| Vesugen increased explant growth by about 19% to 20% and raised expression of the proliferation marker Ki-67 roughly 1.8-fold in old explants and about 2-fold in late-passage endothelial cells. The authors then used molecular docking to argue that the peptide binds a CATC motif in the MKI67 promoter; this is a modeling hypothesis, not a measured interaction. | |||||
| Community-reported3 rows | |||||
| Community subcutaneous course | 1-2 mg per injection | Daily or every other day | Subcutaneous, abdomen or thigh, from a reconstituted vial | 10-20 daysMonths off; repeated once or twice a year | Community resource2026 |
| This wiki page, last verified June 2026, separates three things: the 400 mcg/kg mouse dose, a Russian clinic pattern of low-microgram oral courses for 10 to 20 days, and the 1-2 mg injections described on vendor packaging and forums. It points out that an allometric conversion of the mouse dose gives roughly 2.2-2.5 mg per day for a 70 kg adult and that none of the human figures rests on pharmacokinetic data. | |||||
| Capsule or vial course in the Khavinson pattern | 1-2 Cytomed capsules per day, or 1-2 mg subcutaneously (5 mg vial in 2.5 mL gives 2 mg/mL) | Once daily | Oral capsules swallowed before breakfast, or subcutaneous injection | 10-30 day courses (about 10 days for the vial pattern)Repeated once or twice a year | Community resource2026 |
| A calculator site's August 2026 page treats the Russian capsule and the research vial as two different products that should not be converted into each other, and describes the short pulsed course as the way the Khavinson school used its synthetic peptides. It rates the evidence as low and says the capsule timing advice comes from manufacturer leaflets rather than absorption studies. | |||||
| Manufacturer-style capsule schedule and compounding cycles | 1-2 capsules of 0.2 g (labelled as containing the AKS-2 peptide complex) | 1-2 times daily with meals | Oral capsules; compounded injectable courses described as subcutaneous or intramuscular | 10-30 days per course; compounding pharmacies described as using 10-20 day cyclesRepeat every 4-6 months (capsules) or 2-4 times a year (compounded injections) | Community resource2026 |
| This technical page reproduces the Russian capsule leaflet pattern and states that outside Russia the peptide has no approval or recognized indication and is dispensed off-label. It lists only injection-site pain and occasional redness as reported side effects and gives a half-life of 2 to 4 hours without a citation. | |||||
How a course is commonly described
- Days 1-10: courseCommunity-reported
Community guides describe a short pulse of 1-2 mg subcutaneously each day, or one to two capsules a day, rather than a long titration. No source describes what, if anything, a person should expect to notice during these days.
- Days 10-30: end of courseCommunity-reported
Capsule courses run 10 to 30 days and injectable courses 10 to 20 days in the sources that describe them. The courses stop rather than taper.
- Break: monthsCommunity-reported
Courses are repeated once or twice a year, or every 4 to 6 months, with months off in between. This mirrors the general Khavinson short-peptide pattern and has not been tested against continuous use or against no use.
- Clinical recordClinical
The human reports are uncontrolled: 41 men with atherosclerosis-related erectile dysfunction treated with Vezugen alone and assessed by penile artery flow, and 32 people aged 41 to 83 with multiple chronic conditions given Vesugen and Pinealon and scored by biological-age indices. The second report also found pro-oxidant activity and a fall in circulating CD34-positive stem cells, and neither abstract states a dose, route or course length.
- Preclinical comparisonPreclinical
The only published in vivo dose is 400 mcg/kg a day by intraperitoneal injection for about two months in Alzheimer's model mice, and the culture work used nanogram-per-millilitre concentrations. Nothing in the animal literature describes cycling.
- No human dose-finding, pharmacokinetic or placebo-controlled study of Vesugen exists, and the Russian clinical reports do not state their doses in English. The 1-2 mg community dose is a vendor convention.
- The one unfavourable human finding, a drop in CD34-positive haematopoietic cells and pro-oxidant activity in the 2015 geriatric report, has never been followed up. Tripeptides of this size are expected to clear from plasma within minutes.
- Vesugen is not approved anywhere and is sold as a Russian supplement capsule or as research-grade powder. It is often confused with Vesilute, the bladder peptide in the same product line, and some vendors print the KED sequence for both.
Sources for this section (9)
- Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease
- Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission
- The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people
- Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease
Plus 5 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Overview
Vesugen (also transliterated Vezugen) is the tripeptide Lys-Glu-Asp, known as KED or T-38 in the papers of Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, where it was designed from the amino acid composition of a blood-vessel extract and proposed as a vascular bioregulator that acts on endothelial gene expression. The published evidence consists of cell and tissue culture work, a few rodent experiments including an Alzheimer's mouse model, and three small Russian clinical reports without placebo groups (41 men with vasculogenic erectile dysfunction, 32 older polymorbid patients given Vesugen with Pinealon, and a workplace stress study), almost all from the developers' group. It is sold in Russia as a Cytomed capsule supplement and elsewhere as 5-20 mg research vials; it has no regulatory approval in any country, no registered clinical trial, and no published human pharmacokinetics, and the English abstracts of the human reports do not state the dose used.
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 1
Research on Vesugen
Vesugen, a neuroprotective peptide, shows promise in the field of Alzheimer’s disease and central nervous system (CNS) function.…
What is known and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Not graded
Research on Vesugen
Vesugen, a neuroprotective peptide, shows promise in the field of Alzheimer’s disease and central nervous system (CNS) function. Here are some key points about Vesugen: Memory Improvement: Vesugen has demonstrated the ability to improve memory in elderly…
Amounts recorded for Vesugen
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 1Dose · lower endpointSign in for schedule, duration and source context.1 mg
- 2Dose · upper endpointSign in for schedule, duration and source context.5 mg
Chemistry identifiers
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Sequence
Lys-Glu-Asp
Also listed as
Lys-Glu-Asp, KED peptide, Vezugen, T-38 (Khavinson laboratory code), L-Lysyl-L-glutamyl-L-aspartic acid, CHEBI:159909, SCHEMBL3767701
InChIKey
LLSUNJYOSCOOEB-GUBZILKMSA-N
IUPAC name
(2S)-2-[[(2S)-4-carboxy-2-[[(2S)-2,6-diaminohexanoyl]amino]butanoyl]amino]butanedioic acid
Limitations and unknowns
Sources
1 link carried over from the earlier page, awaiting verification.